Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.60 |
| ▸ | MMP2 | P08253 | 2/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227705 | 0.90 | FOLH1 (0.69) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL31265517 | 0.90 | FOLH1 (0.69) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL31265519 | 0.90 | FOLH1 (0.69) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL22674651 | 0.88 | FOLH1 (0.60) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL25455599 | 0.86 | HTT (0.60) | FOLH1MMP2MMP9HTTCA1 | |
| SCHEMBL17995299 | 0.86 | FOLH1 (0.64) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL14719981 | 0.85 | MAPT (0.61) | FOLH1MMP2MMP9HTT | |
| SCHEMBL14719982 | 0.85 | MAPT (0.61) | FOLH1MMP2MMP9HTT | |
| SCHEMBL30958397 | 0.83 | FOLH1 (0.61) | FOLH1MMP2MMP9HTTSIRT2 | |
| SCHEMBL13251388 | 0.82 | HTT (0.65) | FOLH1MMP2MMP9HTTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | FOLH1 2255/4885MMP2 2377/4885MMP9 1927/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | FOLH1 683/4885MMP2 2674/4885MMP9 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.